NYXOAH SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.92 EUR | -5.11% |
|
-13.82% | +109.39% |
| Apr. 12 | Nyxoah Names New Chief Medical Officer | MT |
| Apr. 12 | Nyxoah S.A. Appoints Maurits Boon as Chief Medical Officer | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 8.78M 9.46M | Sales 2025 * | 36.18M 38.98M | Capitalization | 270M 291M |
|---|---|---|---|---|---|
| Net income 2024 * | -61M -65.73M | Net income 2025 * | -69M -74.35M | EV / Sales 2024 * | 24.7 x |
| Net cash position 2024 * | 52.9M 57M | Net Debt 2025 * | 16.5M 17.78M | EV / Sales 2025 * | 7.91 x |
| P/E ratio 2024 * |
-4.45
x | P/E ratio 2025 * |
-4.82
x | Employees | 147 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nyxoah SA
More recommendations
More press releases
| 1 day | -5.11% | ||
| 1 week | -13.82% | ||
| Current month | -4.29% | ||
| 1 month | -18.91% | ||
| 3 months | +1.83% | ||
| 6 months | +67.04% | ||
| Current year | +109.39% |
1 week
8.92
10.70
1 month
8.3011.45
Current year
3.7917.60
1 year
3.7917.60
3 years
3.7930.00
5 years
3.7930.00
10 years
3.7930.00
| Managers | Title | Age | Since |
|---|---|---|---|
Olivier Taelman
CEO | Chief Executive Officer | 54 | 19-06-30 |
Robert Taub
FOU | Founder | 78 | 09-07-14 |
Loïc Moreau
DFI | Director of Finance/CFO | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kevin Rakin
BRD | Director/Board Member | 63 | 16-06-28 |
Robert Taub
FOU | Founder | 78 | 09-07-14 |
Jürgen Hambrecht
BRD | Director/Board Member | 77 | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 8.92 | -5.11% | 19 492 |
| 24-05-03 | 9.4 | +2.40% | 13,874 |
| 24-05-02 | 9.18 | -1.50% | 27,556 |
| 24-04-30 | 9.32 | -9.95% | 42,936 |
| 24-04-29 | 10.35 | +7.81% | 10,767 |
Real-time Euronext Bruxelles, May 06, 2024 at 11:35 am EDT
More quotes
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah SA's innovative solution platform is based on the Genio® system, a CE-Mark validated, user-centered neurostimulation therapy for obstructive sleep apnea, the world's most common sleep disordered breathing condition.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
9.4
EUR
Average target price
15.5
EUR
Spread / Average Target
+64.89%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +109.39% | 290M | |
| +8.32% | 218B | |
| +7.01% | 184B | |
| +13.20% | 135B | |
| -0.27% | 62.38B | |
| +11.65% | 51.37B | |
| +7.76% | 50.9B | |
| +1.32% | 40.87B | |
| +2.66% | 36.28B | |
| +25.51% | 31.88B |
- Stock Market
- Equities
- NYXH Stock